ribavirin has been researched along with cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrei, G; Balzarini, J; De Clercq, E; Holý, A; Krecmerová, M; Masojídková, M; Naesens, L; Neyts, J; Pohl, R; Snoeck, R | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
2 other study(ies) available for ribavirin and cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
| Article | Year |
|---|---|
Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
Topics: Antiviral Agents; Cell Line; Cytosine; DNA Viruses; Drug Resistance, Viral; Esters; Humans; Magnetic Resonance Spectroscopy; Prodrugs; Retroviridae; RNA Viruses; Stereoisomerism; Structure-Activity Relationship | 2007 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |